Merging empathy with science: solutions for life

WHO WE ARE

We are a medical supply and pharmaceutical company based in Singapore. A lot has changed since we started in 1996; over the past two decades, we have expand our verticals and global position. As we continue to grow, we remain dedicated to our core values – putting our employees, clients, and the community, first.

We are greatly involved in the research and development of masks, respirators, unique pharmaceutical products, and pet health tech.

OUR MISSION

From our big-picture strategy to our daily execution, these statements are what drives our teams and gives us purpose:

1) Provide creative solutions to health challenges by harnessing science, technology, and meaningful relationships.

2) Improve quality of life for the community through holistic solutions.

3) Build healthier, more resilient communities around the world.

COMPANY HISTORY

2023
1996
1998
2000
2001
2003
2005
2007
2009
2014
2016
2017
2018
2019
2020
2021
2022

2023

  • Initial public offering (IPO) fully subscribed on SGX
  • Entered into a private label supply agreement with McKesson Medical-Surgical Inc. (“McKesson”) for the supply of medical and surgical supplies and devices

1996

Incorporation of Pasture Pharma in Singapore 

 

1998

Exclusive Distributor for Byk Gulden (Altana) 

 

2000

Incorporation of Pacific Biosciences Singapore

 

2001

Exclusive distributor of Chiron Vaccines (Novartis) 

Exclusive distributor of Genzyme SE Asia (Sanofi) 

 

2003

Largest Supplier of Influenza vaccines to Singapore government during SARS 

 

2005

Invest in R&D for anti-viral mask 

Mask manufacturing facility based in Taiwan 

 

2007

NIOSH approval for anti-viral mask, first in the world 

 

2009

U.S FDA approval of 2 pandemic N95 respirators, second in the world 

U.S FDA recommended Pasture F550G and A520G for use to protect against H1N1 

 

2014

International Procurement & Distribution Service of Medicinal Products

 

2016

Seven N95 respirators and masks approved by U.S FDA 

Invest in Hart-S, first ODS manufacturing and research 

 

2017

2nd mask manufacturing facility based in China 

 

2018

3rd mask manufacturing facility based in China

 

2019

4th mask manufacturing facility based in China 

PIC/S approval in facility manufacturing ODS 

 

2020

Planned 5th mask manufacturing facility in Asia 

 

2021

5th mask manufacturing facility opened in Thailand

Supplied more than 100 million Surgical N95 Respirators and Masks globally

Exclusive Distributor for CanSino Biologics with single-shot COVID-19 vaccine in Singapore

2022

Attained Halal Certification for Pasture Surgical N95 Respirators for Healthcare and Public Use

OUR TEAM

Board of Directors

Mr. Lloyd Soong

Executive Chairman and Chief Executive Officer

Lloyd Soong, CEO and Director of Pasture Holdings

Mr. Soong founded the Group in 1996 after seeing an unmet need for a distribution company that focused on specialty medications and medical devices. He oversees the overall business, operations, and performance of the Group. He has over 39 years of experience in the pharmaceutical and medical supplies and devices industry. Mr. Soong has a Master of Business Administration (Strategic Marketing) from the University of Hull, England. Lloyd’s personal interests are rooted in the R&D of innovative products that can improve one’s quality of life.

Mr. Prashanth Palepu

Non-Executive Director

Mr. Prashanth Palepu
Non-Executive Director

Mr. Palepu is currently the chief operating officer of Palepu Pharma, where he spearheads developments within the supply chain process. He is a member of the Entrepreneurs Organisation in India, a global platform for entrepreneurs. Mr. Palepu has a Bachelor of Commerce from Loyola College, and a Master of Science in Supply Chain and Logistics Management from the University of Warwick.

Headshot of board member Michael Lim

Mr. Michael Lim

Non-Executive and Lead Independent Director
Headshot of board member Michael Lim

Mr. Michael Lim
Non-Executive and Lead Independent Director

Mr. Lim is currently the chief financial officer of Fuelcore Pte. Ltd. He has over 30 years of experience in corporate finance, corporate restructuring and tax planning. Mr. Lim completed his professional education with the Institute of Chartered Accountants in England and Wales.

Profile photo of Claudia Teo for board member profiles

Ms. Claudia Teo

Non-Executive and Independent Director

Ms. Claudia Teo
Non-Executive and Independent Director

Ms. Claudia Teo is a Non-Executive and Independent Director and was appointed to our Board on 29 March 2023.

 

Ms. Teo is currently the head of the corporate and financial services practice group in Harry Elias Partnership LLP (“HEP”). She has over 20 years of experience in advising on landmark transactions in corporate finance, including initial public offerings on the SGX-ST, placements and rights issues, privatisations, compliance and corporate governance issues. Ms. Teo joined HEP in 2006 where her main areas of practice are in corporate finance and mergers and acquisitions transactions throughout Asia.

 

Between June 2015 to October 2021, Ms. Teo served as an independent non-executive director of an SGX Catalist listed company, where she served as the chairperson of the nominating committee and the risk management committee, and was also a member of the audit committee and remuneration committee.

 

Ms. Teo was recommended in the 2015 edition of the Legal 500 Asia-Pacific and also in the 2014 edition of Asialaw’s Leading Lawyer publication. Ms. Teo is also a non-executive director and a member of the investment committee and the governance and risk committee of Ren Ci Hospital, a Singapore charity healthcare institution. She is also a member of the investment committee of Singapore Hokkien Huay Kuan and an independent director of The Hokkien Foundation.

 

Ms. Teo completed her Bachelor of Laws (Hons) at the University of Manchester. She is dually qualified as a barrister and a solicitor of England and Wales and is admitted to the Rolls of Solicitors of Hong Kong. Ms. Teo was called to the Singapore Bar in 1990.

Ms. Sharon Low

Non-Executive and Independent Director

Ms. Sharon Low

Ms. Low is a biochemist and entrepreneur.  She worked on animal vaccines at NUS research laboratories and subsequently was founder and Managing Director of stem cell service company StemLife Berhad, where she led regional growth initiatives as well as its public listing and strategic sale.  She currently serves as a non-executive director of KRZ Limited (HK).  Ms. Low has a Bachelor of Science with honors in Biochemistry, Molecular Biology & Biotechnology from the University of Bristol, UK.

Executive Staff

Ms. Claire Soong

Alternate Director to Lloyd Soong and Digital Marketing Manager
Claire Soong Digital Marketing Manager

Ms. Claire Soong
Alternate Director to Lloyd Soong
Digital Marketing Manager

Ms. Soong has a Bachelor of Commerce from McGill University. She is the Group’s Digital Marketing Manager, overseeing the digitalization, marketing, and “furlife” mobile application. Prior to joining the Group, she was a content strategist at Maker Lab for Google APAC.

Ms. Ho Huey-Yi

Chief Pharmacist

Ms. Ho Huey-Yi
Chief Pharmacist

Ms. Ho is responsible for managing the pharmaceutical regulatory affairs for our Group, including controlled drugs management and quality management. She also manages the Group’s daily business operations. Ms. Ho has over 19 years of experience in the pharmaceutical industry. She has a Bachelor of Science (Pharmacy) from the National University of Singapore, and has been certified as a registered pharmacist by the Singapore Pharmacy Board.

ERP Implementation Success Stories from AFON

– Pasture Group

Pasture Pharma Boosts Sales Turnover by 100%; Improves Order and Inventory Tracking

ERP Implementation Success Stories from AFON

– Pasture Group

Pasture Pharma Boosts Turnover by 100%; Improves Order and Inventory Tracking